New combo therapy aims to clear cloudy corneas by zapping and blocking blood vessels
NCT ID NCT07642960
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a two-step treatment for corneal neovascularization, where abnormal blood vessels grow on the clear front part of the eye. First, doctors use a fine needle with heat to seal off the vessels, then inject a drug called bevacizumab to prevent regrowth. The trial will enroll 51 adults with stable corneal blood vessels and measure how much the vessels shrink over 12 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Bevacizumab (a drug that blocks blood vessel growth) and fine-needle diathermy (a procedure using heat to seal off abnormal blood vessels)
- What this could lead to
- If successful, this combination could offer a safe, effective way to reduce abnormal corneal blood vessels and potentially improve vision in affected patients.
- What could go wrong
- This is a small, early-phase trial with only 51 participants, so results may not apply to everyone. Risks include infection, scarring, or the blood vessels returning.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CORNEAL NEOVASCULARISATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
HoChiMinh City Eye Hospital
RECRUITINGHo Chi Minh City, Xuan Hoa, 72400, Vietnam